Production of human papillomavirus 6b L1 virus-like particles incorporated with enhanced green fluorescent whole protein in silkworm larvae

著者	Muthukutty Palaniyandi, Kato Tatsuya, Park Enoch Y.
journal or publication title	Biotechnology and Bioprocess Engineering
volume	18
number	3
page range	514-519
year	2013-06-01
出版者	Springer
権利	(C) The Korean Society for Biotechnology and Bioengineering and Springer 2013. The final publication is available at Springer via http://dx.doi.org/10.1007/s12257-012-0719-5
URL	http://hdl.handle.net/10297/7838

doi: 10.1007/s12257-012-0719-5

- 1 **Production of human papillomavirus 6b L1**
- 2 **virus-like particles incorporated with enhanced**
- 3 **green fluorescent whole protein in silkworm**
- 4 **larvae**
- 5 **Palaniyandi Muthukutty, Tatsuya Kato, Enoch Y. Park***

Palaniyandi Muthukutty, Enoch Y. Park*

Laboratory of Biotechnology, Integrated Bioscience Section, Graduate School of Science and Technology,
Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan.

Tel. & Fax: +81-54-238-4887

E-mail: acypark@ipc.shizuoka.ac.jp

Tatsuya Kato, Enoch Y. Park

Laboratory of Biotechnology, Department of Applied Biological Sciences, Faculty of Agriculture,
Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan.

Abstract Using human papillomavirus (HPV) as subunit vaccine and its manipulation of surface loops is current trend in research. Since the atomic model of L1 protein conformations were deciphered, their manipulations of epitopes bring multivalent vaccines. Here, in the present study we had expeditiously manipulated antigenic loops of HPV 6b L1 capsid proteins in the amino acid regions 174–175 (L1:174EGFP) and 348–349 (L1:348EGFP) with whole enhanced green fluorescent protein (EGFP), expressed in the silkworm larva using *Bombyx mori* nucleopolyhedrovirus (BmNPV) bacmid technology. The expressed proteins were partially purified using sucrose density-gradient centrifugation and size-exclusion chromatography (SEC). The display of EGFP in virus-like particles (VLPs) was confirmed by immuno-fluorescence microscopy, western blots and immune-transmission electron microscopy (immuno-TEM). There was higher expression of EGFP incorporated L1:174EGFP than L1:348EGFP. Hydrodynamic diameter of VLPs was corroborated by dynamic light scattering, confirming the size of expected range of around 160 nm and substantiating the incorporation of EGFP. From immuno-TEM, each L1:EGFP VLP formed small particles, suggesting that small particles of L1:EGFP fusion protein were aggregated. Our study illustrates that incorporation of whole protein can efficiently form chimeric VLPs, without hindering the

- 23 conformation. HPV L1 protein accommodated a whole protein on its antigenic loop as a
- 24 small particle, but inserted whole protein was unstable.
- 25 **Keywords:** virus-like particle, human papillomavirus, L1 protein, silkworm, BmNPV
- 26 bacmid, display of protein

1. Introduction

Human papillomavirus are group of double stranded DNA viruses, causing low risk warts to cervical cancers in humans. Human papillomavirus 6b L1 (HPV6b L1) virus infects mucosal epithelial tissues in genital areas causing benign lesions [1]. The structural protein of HPV consists of L1 and L2 capsid proteins, L1 having functions of virion formation and cell association where the later involved in membrane penetration, post-entry trafficking, and genome encapsidation. The L1 is the primary capsid protein approximately of 55 kDa, where 360 monomeric capsomere proteins assemble as 72 pentamers to form T=7 icosahedral lattice. The fully assembled L1 virus particle has a size of around 60 nm in diameter. Conformation of L1 capsid protein assembly and its five surface antigenic loops BC, DE, EF, FG and HI were solved using crystallographic studies [2, 3].

Recombinant L1 capsid protein alone can be expressed in expression systems to form VLPs, which can elicit immune response when used as subunit vaccines [4-8]. Also, display of foreign protein in VLPs makes elicit immune response against both the proteins [9]. Fusing or inserting epitopes or proteins on the terminal regions of capsid protein doesn't interfere with the conformations of VLPs. It is proved that a single VLP can be used as a multivalent drug against disease and tumor targeting entities [10–13].

Previously, we had showed that the expression of full length HPV 6b L1 capsid protein could form efficiently VLPs when expressed in silkworm-bacmid system [14]. In this work, we present incorporation of whole EGFP into two antigenic loops of HPV 6b L1, expression using bacmid technology, and characterization of the VLP assembly.

2. Materials and Methods

2.1. Expression of HPV 6b L1 proteins

Two different surface loops incorporated with EGFP in HPV 6b L1 capsid protein was constructed as described previously [14]. Briefly, each HPV 6b L1:EGFP fusion gene was obtained by two-step PCR. In addition, an EGFP gene was amplified by PCR and, a second PCR was performed using the amplified EGFP and the two amplified truncated L1 genes as a template and primers, respectively, to obtain L1:174EGFP fusion gene. The EGFP gene was inserted into EF loop between 174 and 175 amino acids in an L1-coding gene. Moreover, linker-region coding sequences (GGGGSGGGGS) were also added between L1 and EGFP genes. By this two-step PCR, the EGFP gene was inserted into HI loop between 348 and 349 amino acids in an L1-coding gene (L1:348EGFP) was obtained. Each amplified fusion gene was inserted at *EcoRI-KpnI* site in pFastBac1. The recombinant BmNPV CP⁺ bacmid containing each HPV 6b L1:EGFP fusion gene was constructed according to the protocol described previously [14, 15]. The fifth instar

Bombyx mori larvae were individually injected with 4 µg of chimeric HPV 6b L1:EGFP bacmids and reared in 25°C incubator [15]. After 7 days, fat body is collected from each silkworm and stored at -80°C until use.

2.2. Purification of HPV 6B L1:EGFP chimeric VLPs

Extraction of expressed protein was achieved by sonicating the fat body using PBS (pH 7.4) containing 0.1% Triton-X100. The lysates were clarified using centrifugation at 30000 g for 15 min. The clarified lysates were loaded on top of 25–60% sucrose density-gradient cushion and ultracentrifuged at 122 000 g for 3 h at 4°C, and ultracentrifuged samples were collected in every 0.5 ml of fraction from the top of the tube to the bottom. The fractions containing target bands were detected by western blots. The fractions containing HPV 6b L1:EGFP chimeric VLPs were collected and loaded into HiLoad Superdex™ 16/60 200 prep grad column which was equilibrated with 3 column volumes of PBS (pH 7.4). The samples were eluted with PBS (pH 7.4) plus 0.5 M NaCl; 5 ml fractions were collected in fresh tubes and stored at 4°C for further analysis.

2.3. Immunoblotting

Fractions from sucrose density-gradient and size exclusion chromatography were subjected to immuno-analysis. Thirty µl of the fraction was mixed with 10 µl of sample

buffer and 20 μ l were loaded to SDS-PAGE gels, respectively. For western blot, the gel was transferred to PVDF membrane using Trans-blot[®] semi dry electrophoretic transfer cell (Bio-Rad, Hercules, CA, USA) at 15 V for 1 h. After transfer the membrane was blocked with 5% skim milk in Tris buffered saline with 0.5% tween 20 (TBS-T) for 1 h. Washed three times with TBS-T and incubated with 1:5,000-diluted mouse anti-EGFP antibody (Clontech, Mountain View, CA, USA) for overnight at 4°C. Anti-mouse secondary antibody conjugated with horseradish peroxidase (HRP) (1:10,000 diluted, GE Healthcare Japan, Tokyo, Japan) was used against primary antibody, and incubated for 1 h at room temperature. Detection was carried out using Versa Doc Imager and analyzed using Quantity-One software (Bio-Rad).

2.4. Size analysis of chimeric VLPs

The partially purified HPV 6b L1:EGFP chimeric variants were analyzed for hydrodynamic property and homogeneity using Dynamic Light Scattering (DLS) assay. One ml of PBS (pH 7.4) was mixed with L1:174EGFP and L1:348EGFP individually and diluted to 0.1 mg/ml. The samples were analyzed and calculated based on 10 successive measurements at 25°C using Zetasizer nano ZS DLS analyzer fitted with 532 nm laser lamps (Malvern Instruments, UK).

2.5. Immuno-transmission electron microscopy (Immuno-TEM)

The chimeric L1:EGFP VLPs were immobilized on the carbon-coated grids. Dried for 15 min and blocked using 3% BSA for 30 min. Primary EGFP antibody (Clontech) diluted to 100-fold in blocking buffer (Tris-BSA) and adsorbed to grids for 1 h. After washing 5 times with TBS, the grids were soaked in 10 nm gold conjugated 1: 200 diluted mouse anti-IgG+IgM antibodies (BBI International, Ltd., Cardiff, UK) for 1 h. After washing, the grids were stained with 2% phosphotungstic acid and dried for 30 min. VLPs were then observed by TEM (JEM 2100, Japan) at 40,000× magnifications.

2.6. Confocal laser scanning microscopy

Fresh fat body cells containing HPV 6b L1 and L1:EGFP chimeric VLPs were washed three times in PBS, and fixed with 4% formaldehyde solution for 20 min at room temperature. Cells were permeabilized using 0.1% Triton-X100 in PBS for 20 min. Then the cells were subjected to blocking with 3% BSA for 1 h and incubated with 1:100 dilution of EGFP primary antibody. Alexa fluor® 594 goat anti-mouse IgG (H+L) (Life Technol. Japan Co. Tokyo, Japan) was used as a secondary antibody. The cells were counterstained for nuclei using 4,6-diamidino-2-phenylindole (DAPI). Samples were observed using LSM 700 microscope (Zeiss, Jena, Germany) and images were analyzed by Zen2010 software.

3. Result and discussion

3.1. Designing incorporation of EGFP in HPV 6b L1 VLPs

Chimeric HPV 6b L1 VLPs displaying EGFP as a model protein was designed in such a way that the incorporation was done in surface antigenic loops where the incorporated protein can be displayed. PCR was performed to insert the whole EGFP protein into the HPV 6b L1 EF and HI epitopes by specific primers (Fig. 1A). Previously, it was demonstrated that bovine papillomavirus (BPV) L1 protein inserted human mucin 1 (MUC1) peptide into its HI loop can assemble into VLP, but BPV L1 protein inserted the same peptide into BC and DE loops can not be assembled [16]. In addition, EF loop localizes the outermost of L1 pentamer [17]. Therefore, EF and HI loops were selected to insert EGFP in this study. Moreover, It was previously reported that use of flexible linkers to allow the incorporated whole protein to flexibly move to take conformation [18]. Therefore, we added a double GGGGS linker sequence that was placed in the N-terminal and C-terminal of the EGFP protein. Since EGFP has green fluorescence when expressed EGFP has correct conformation, whether expressed L1:EGFP chimeric proteins have correct conformation or not can be easily confirmed by its green fluorescence. The chimeric constructs were ligated in the *EcoRI* and *KpnI* regions of

pFastbac I plasmid and transformed to BmNPV CP⁻ bacmid to express in silkworm larvae (Fig. 1B).

3.2. Expression and purification of HPV 6b L1:EGFP chimeric VLPs

Expression of each HPV 6b L1:EGFP chimeric VLPs was confirmed in silkworm larvae by observing under UV transilluminator (data not shown). The fat body samples were sonicated and the clarified lysates were applied to 25–60% sucrose density-gradient ultracentrifugation and the fraction (Fractions 3–6 in all 10 fractions) containing 83 kDa of HPV 6b L1:174EGFP and L1:348EGFP chimeric VLPs along with degraded proteins were confirmed by western blot (Fig. 2). The expression levels of the two constructs varied, and L1:174EGFP (150 µg/larval hemolymph ml) was comparatively higher than L1:348EGFP (62 µg/larval hemolymph ml). Fractions containing each L1:EGFP chimeric VLP were collected and further purified by size exclusion chromatography using Hiload superdex[™] 16/60 200 prep grade column. L1:174EGFP and L1:348EGFP chimeric VLPs were eluted at 35–55 ml and 40–50 ml, respectively, on this SEC column. Partially purified fractions were recovered.

3.3. Confirmation of size and structural integrity

To determine the conformation of HPV 6b L1:EGFP chimeric VLPs, dynamic light scattering was carried out [19]. The sizes of chimeric L1:174EGFP (Fig. 3A) and L1:348EGFP (Fig. 3B) were 156 nm and 155 nm, respectively (at pH 7.4, 25°C), which are bigger than HPV 6b L1 VLP alone (~ 60 nm). Size of HPV L1 VLP is normally 55 nm in diameter. In this study, each purified L1:EGFP chimeric VLP has approximately 155 nm in diameter. From immuno-TEM images, these purified chimeric VLPs formed small particles and these particles were aggregated. In addition, gold nanoparticles were observed on the small particles and aggregates composed of each chimeric VLP, indicating that EGFP were displayed on the surface of these particles.

3.4. Localization of HPV 6b L1:EGFP chimeric VLPs in fat body cells of silkworm larvae

To prove that the HPV 6b L1 chimeric VLPs with EGFP incorporation expressed in silkworm larvae are having native conformation, the fat body was immuno-labeled with EGFP antibodies [20]. As shown in Fig. 4, the EGFP fluorescence at 488 nm was observed in cytoplasm of cells where L1:174EGFP or L1:348EGFP was expressed. With immuno-labeling with Alexa Fluor® 594, we can confirm that its red fluorescence was coinciding with the EGFP fluorescence, indicating that each expressed L1:EGFP chimeric VLPs had EGFP fluorescence. This result is contradictory to previous report,

which mentions these L1:EGFP chimeric VLPs did not show EGFP fluorescence [14].

In previous study, the fat body homogenate was applied to HiTrap heparin affinity column chromatography and Mono S 5/50GL column chromatography in series. But after purification any fluorescence of each purified L1:EGFP chimeric VLP was not detected (Data not shown). In this study, the purification was modified as follow; the VLPs were separated from the fat body homogenate by sucrose density-gradient ultracentrifugation, and were applied to HiLoad Superdex 16/60 200 prep grad column. However, any fluorescence of each purified L1:EGFP chimeric VLPs was not detected. This indicates that purification of HPV 6b L1 VLPs using columns affects the structural integrity or immune response. Kim *et al.* also reported that choice of resin-bound ligand affects the structural and immunogenicity of column-purified human papillomavirus type 16 VLPs [21]. On the other hand, fat body cells and silkworm larvae where each L1:EGFP chimeric VLP expressed showed EGFP fluorescence. It suggests that L1:174EGFP and L1:348EGFP chimeric VLPs had EGFP fluorescence *in vivo*, but after extraction and purification processes, its EGFP fluorescence disappeared because of its instability or conformational change *in vitro*.

4. Conclusion

Display of foreign proteins on the surface of VLPs has many advantages, for example use as multiple antigenic vaccines or trafficking studies of signaling. Our study suggests that incorporating whole protein in VLPs can be helpful in future incorporations like other L1 capsid protein/epitopes or mutualistic/opportunistic diseases associated with papillomavirus. This technology can provide the formation of chimeric VLPs using epitope loop without compromising the conformation of VLPs.

Acknowledgment

We would like to thank Dr. Vipin Kumar Deo for helping in observing electron microscopy samples. Also, Dr. Makoto Ogata for assisting in analyzing chimeric VLPs in dynamic light scattering. This work was supported by Promotion of Nano-Technology Research to support Aging and Welfare Society from the Ministry of Education, Culture, Sports, Science and technology (MEXT), Japan. Muthukutty Palaniyandi was supported by MEXT, Japan

References

1. McMurray, H. R., D. Nguyen, T. F. Westbrook, and D. J. McAnce (2001) Biology of human papillomaviruses. *Int. J. Exp. Pathol.* 82: 15-33.

- 199 2. Modis, Y., B. L. Trus, S. and C. Harrison (2002) Atomic model of the
200 papillomavirus capsid, *EMBO J.* 21: 4754-4762.
- 201 3. Bishop, B., J. Dasgupta, M. Klein, R. L. Garcea, N. D. Christensen, R. Zhao, and X.
202 S. Chen (2007) Crystal structures of four types of human papillomavirus L1 capsid
203 proteins: understanding the specificity of neutralizing monoclonal antibodies. *J.*
204 *Biol. Chem.* 282: 31803-31811.
- 205 4. Chen, X. S., G. Casini, S. C. Harrison, and R. L. Garcea (2001) Papillomavirus
206 capsid protein expression in *Escherichia coli*: purification and assembly of HPV11
207 and HPV16 L1. *J. Mol. Biol.* 307: 173-182.
- 208 5. Kim, S. N., H. S. Jeong, S. N. Park, and H. J. Kim (2007) Purification and
209 immunogenicity study of human papillomavirus type 16 L1 protein in
210 *Saccharomyces cerevisiae*. *J. Virol. Methods.* 139: 24-30.
- 211 6. Fernandez-San Millan, A., S. M. Ortigosa, S. Hervas-Stubbs, P. Corral-Martinez, J.
212 M. Segui-Simarro, J. Gaetan, P. Coursaget, and J. Veramendi (2008) Human
213 papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into
214 virus-like particles that are highly immunogenic, *Plant Biotechnol. J.* 6: 427-441.

- 215 7. Arora, U., P. Tyagi, S. Swaminathan, and N. Khanna (2012) Chimeric Hepatitis B
216 core antigen virus-like particles displaying the envelope domain III of dengue virus
217 type 2. *J. Nanobiotechnol.* 10: 30-35.
- 218 8. Zhu, S., X. Xue, J. Liu, L. Lu, P. Zhao, J. Wang, W. Li, and L. Zhang (2010)
219 Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice.
220 *Acta. Biochim. Biophys. Sin.* 42: 515-521.
- 221 9. Peng, S., I. H. Frazer, G. J. Fernando, and J. Zhou (1998) Papillomavirus virus-like
222 particles can deliver defined CTL epitopes to the MHC class I pathway. *Virology*
223 240: 147-157.
- 224 10. Sadeyen, J. R., S. Tourne, M. Shkreli, P. Y. Sizaret, and P. Coursaget, (2003)
225 Insertion of a foreign sequence on capsid surface loops of human papillomavirus
226 type 16 virus-like particles reduces their capacity to induce neutralizing antibodies
227 and delineates a conformational neutralizing epitope. *Virology* 309: 32-40.
- 228 11. Murata, Y., P. M. Lightfoot, R. C. Rose, and E. E. Walsh (2009) Antigenic
229 presentation of heterologous epitopes engineered into the outer surface-exposed
230 helix 4 loop region of human papillomavirus L1 capsomeres. *Virol. J.* 6: 81-91.
- 231 12. Windram, O. P., B. Weber, M. A. Jaffer, E. P. Rybicki, D. N. Shepherd, and A.
232 Varsani (2008) An investigation into the use of human papillomavirus type 16

233 virus-like particles as a delivery vector system for foreign proteins: N- and
 234 C-terminal fusion of GFP to the L1 and L2 capsid proteins. *Arch. Virol.* 153:
 235 585-589.

236 13. Varsani, A., A. L. Williamson, D. de Villiers, I. Becker, N. D. Christensen, and E.
 237 P. Rybicki (2003) Chimeric human papillomavirus type 16 (HPV-16) L1 particles
 238 presenting the common neutralizing epitope for the L2 minor capsid protein of
 239 HPV-6 and HPV-16. *J. Virol.* 77: 8386-8393.

240 14. Palaniyandi, M., T. Kato, and E. Y. Park (2012) Expression of human
 241 papillomavirus 6b L1 protein in silkworm larvae and enhances green fluorescent
 242 protein displaying on its virus-like particles. *Springer Plus* 1:29-34.

243 15. Kato, T., F. Suzuki, and E. Y. Park (2011) Purification of functional baculovirus
 244 particles from silkworm larval hemolymph and their use as nanoparticles for the
 245 detection of human prorenin receptor (PRR) binding. *BMC Biotechnol.* 11: 60-69.

246 16. Pejawar-Gaddy, S., Y. Rajawat, Z. Hilioti, J. Xue, D. F. Gaddy, O. J. Finn, R. P.
 247 Viscidi, and I. Bossis (2010) Generation of a tumor vaccine candidate based on
 248 conjugation of MUC1 peptide to polyionic papillomavirus-like particles. *Cancer*
 249 *Immunol. Immunother.* 59: 685-1696.

250 17. Bishop, B., J. Dasgupta, M. Klein, R. L. Garcea, N. D. Christensen, R. Zhao, and X.
251 S. Chen (2007) Crystal structures of four types of human papillomavirus L1 capsid
252 proteins: understanding the specificity of neutralizing monoclonal antibodies. *J.*
253 *Biol. Chem.* 282: 31803-31811.

254 18. Kratz, P. A., B. Bottcher, and M. Nassal (1999) Native display of complete
255 foreign protein domains on the surface of hepatitis B virus capsids. *Proc. Natl.*
256 *Acad. Sci. USA* 96: 1915-1920.

257 19. Mach, H., D. B. Volkin, R. D. Troutman, B. Wang, Z. Luo, K. U. Jansen, and L.
258 Shi (2006) Disassembly and reassembly of yeast-derived recombinant human
259 papillomavirus virus-like particles (HPV VLPs). *J. Pharm. Sci.* 95: 2195-2206.

260 20. Singh, P., G. Destito, A. Schneemann, and M. Manchester (2006) Canine
261 parvovirus-like particles, a novel nanomaterial for tumor targeting. *J.*
262 *Nanobiotechnol.* 4: 2-12.

263 21. Kim, H.J., S.J. Lim, H.-L. Kwang, and H.-J. Kim (2012) The choice of resin-bound
264 ligand affects the structural and immunogenicity of column-purified human
265 papillomavirus type 16 virus-like particles. *PLoS One* 7:4.
266

Figure legends

Fig. 1. Schematic representation of chimeric HPV 6B L1:EGFP construction. Using PCR technology whole protein EGFP was constructed (A), the constructed HPV 6b L1:EGFP chimeric VLPs were ligated with pFastbac1 *Eco*RI and *Kpn*I restriction site and transformed to *E. coli* BmDH10 Bac CP⁺ and the bacmid was injected to silkworm larvae for expression.

Fig. 2. Immuno-analysis of chimeric HPV 6b L1:EGFP. Sucrose density-gradient fractions (3, 4,5and 6) of HPV 6b L1:174EGFP (A) and HPV 6b L1:348EGFP (B) were collected separately in fresh collection tubes and analyzed by western blots.

Fig. 3. Hydrodynamic size, negative staining and immuno-TEM of chimeric VLPs. Partially purified HPV 6b L1:174EGFP (A) and HPV 6b L1:348EGFP (B) were measured for mean size by dynamic light scattering. Electron microscopy of partially purified HPV 6b L1:174EGFP and HPV 6b L1:348EGFP stained with 2% phosphotungstic acid. VLPs were immuno labeled with colloidal gold nanoparticles of 10 nm against EGFP primary antibody. Bars denote 100 nm.

Fig. 4. Expression of chimeric VLPs in fat body cells. Expressed L1:174EGFP (A), L1:348EGFP (B) and HPV L1 (C). Fat body were fixed and permeabilized using 0.1%

284 Triton-X100 and probed with EGFP primary antibody and labeled using Alex Flour
285 594[®]; counterstained with DAPI and observed under confocal microscope. Bars denote
286 20 μm .

Fig.1. Palaniyandi et. al.

A

B